A 15-year study from EUHASS reveals thrombotic rates in patients with inherited bleeding disorders treated with concentrates or bispecific antibodies. This research provides valuable insights into the safety profiles of these treatment modalities.
thrombotic rates in individuals with inherited bleeding disorders treated with concentrate or bispecific antibody fifteen year euhass data
Original title: “Thrombotic rates in individuals with inherited bleeding disorders treated with concentrate or bispecific antibody. Fifteen-year EUHASS data.”